1.a. Full Title: Common polymorphisms of ALOX5 and ALOX5AP and the risk of coronary artery disease

b. Abbreviated Title (Length 26 characters): ALOX5, ALOX5AP and CAD

2. Writing Group:
Writing group members: Themistocles L. Assimes, Joshua W. Knowles, Thomas Quertermous

Other authors will include: Kelly Volcik (ARIC), Hooman Allayee, Eric Boerwinkle (ARIC), Megan Grove (ARIC), Audrey Southwick, Carlos Irbibarren, Alan S. Go, Steve Sidney, Mark A. Hlatky, Stephen P. Fortmann, Richard M. Myers, Neil Risch

Although there are a considerable number of authors, all of them have contributed to this work. The studies described in the paper (ADVANCE, ARIC and CARDIA) are all large, multi-center studies with their own publication requirements. All of the proposed authors have read this manuscript proposal and have given their permission for it to be submitted to the ARIC publications committee.

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. _TA____ [please confirm with your initials electronically or in writing]

First author: Themistocles L. Assimes
Division of Cardiovascular Medicine
Stanford University School of Medicine
Falk CVRC
300 Pasteur Dr
Stanford, CA 94305
email: tassimes@cvmed.stanford.edu
Tel: 650-498-4154
Fax: 650-725-1599

Corresponding/senior author (if different from first author correspondence will be sent to both the first author & the corresponding author):
Address:
3. Timeline:
ARIC statistical analysis: July-Sept 2007
Manuscript revision: Oct 2007
Manuscript submission: Oct 2007

4. Rationale:
To uncover novel genetic modifiers of CAD, the ADVANCE study (Atherosclerotic Disease, VAscular functioN, and genetiC Epidemiology) a collaborative effort between Stanford and Kaiser Permanente of Northern California (KPNC), was initiated. ADVANCE is a large population based candidate gene association study of subjects receiving care within KPNC. Single nucleotide polymorphism (SNP) discovery and sequencing was performed on ~100 candidate genes.

Recent human genetic studies have implicated allelic variants of the leukotriene pathway genes *ALOX5* (encoding arachidonate 5-lipoxygenase, 5LO) and *ALOX5AP*, (encoding 5-LO activating protein, ALOX5AP) in the pathogenesis of atherosclerotic disease. We tested whether single nucleotide polymorphisms (SNPs) in *ALOX5* and *ALOX5AP* are associated with clinically significant CAD in the Atherosclerotic Disease, VAscular FuNction, & GenetiC Epidemiology (ADVANCE) study.

ADVANCE is a population-based case-control study of subjects receiving care within Kaiser Permanente of Northern California including a subset of participants of the Coronary Artery Risk Development in Young Adults (CARDIA) study. We first resequenced the promoter, exonic, and splice site regions of *ALOX5* and *ALOX5AP* and then genotyped 7 SNPs in *ALOX5* and 6 SNPs in *ALOX5AP* in 1552 cases with clinically significant CAD and 1583 controls (including 1219 cases and 1059 controls of white/European ancestry). Our study had over 90% power to detect Odds ratios of 1.3 or greater for SNPs with a minor allele frequency of 15%.

We detected a nominally significant association of the minor allele of a common SNP (rs12762303, minor allele frequency of 15% in whites) in the promoter region of *ALOX5* and CAD in white/European subjects. This SNP was tightly linked to variation at the variable tandem repeat polymorphism previously associated with carotid intima-media thickness (IMT). After adjustment for traditional risk factors, the minor allele was associated with a significantly increased risk of CAD (Odds ratio, 1.31; 95% confidence interval, 1.10-1.56; p = 0.015). However, this finding was not consistent across other race/ethnic groups.

To avoid reporting spurious associations, we sought to replicate our findings in an independent cohort from the Atherosclerosis Risk in Communities study (ARIC), a prospective investigation of atherosclerosis in 15,792 white and African American individuals begun in 1987. We genotyped the promising SNP from *ALOX5* in the ARIC cohort and will perform an analysis in the ARIC cohort to look for an association of these SNPs with CAD. Our power to detect an association in the ARIC cohort is > 80%.
5. Main Hypothesis/Study Questions:

1. To estimate the frequency distribution of one ALOX5 SNP in the ARIC cohort
2. In a race specific manner to evaluate the association of this SNP with CHD events as well as CVD events (as defined by previous ARIC publications 1).
3. To compare the HRR for this SNP in incident fatal CHD vs. all incident CHD.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

Please note that this manuscript is part of an ongoing collaboration with the ARIC group. We will follow the same strategy as was used in our recently approved manuscript: ARIC MS# 1168, “A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease” as well as our other manuscript MS # 1212 “Polymorphisms in the LOX-1 gene OLR1 and the risk of coronary disease”. The main people responsible for the ARIC data analysis are Kelly Volcik and Eric Boerwinkle and they were also involved in the preparation of MS# 1168 and MS#1212.

The usual DNA restriction, ethnic group and missing data exclusion criteria will be used. Analysis will generally be performed as has been done in previous ARIC manuscripts 1. Exclusions will include the following: 1) positive or unknown history of prevalent CHD or stroke or history of TIA/stroke, 2) prohibited use of DNA, 3) ethnic background other than white or African American, as well as African Americans not from Jackson or Forsyth. For incident CHD analyses, we will use the variable in_02sp; analyses for CVD will combine incident CHD and incident stroke cases (in02dp). Covariates to be included in the analyses include age, gender, race, field center, HDL and total cholesterol, BMI, smoking, diabetes and hypertension status.

7.a. Will the data be used for non-CVD analysis in this manuscript? ____ Yes _x___ No

b. If Yes, is the author aware that the file ICTDER02 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used? ____ Yes _____ No

(This file ICTDER02 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? ____x_ Yes ____ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER02 must be used to
exclude those with value RES_DNA = “No use/storage DNA”?
  __x__ Yes    ____ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at:  http://www.cscc.unc.edu/ARIC/search.php

  __x___ Yes    ________ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

   Our groups will be collaborating on several manuscripts as governed by the ancillary study proposal listed below.

11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?    __x__ Yes    ____ No

11.b. If yes, is the proposal

  __x_  A. primarily the result of an ancillary study (list number* 2006.01 __)

     ____ B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* __________  __________

 '*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

References